$2.66
Value $51M
AYTU and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$2.66
Value $51M
$137.78
Value $341B
Aytu BioPharma (AYTU) has a market value of $51M and Merck & Company (MRK) $341B. Over the last year, with dividends, AYTU moved +27.3% and MRK +58.8%. Dividend yield: AYTU none, MRK 2.47%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AYTU$51M
MRK$341B
MRK is 6,627 times AYTU
Revenue, 12 months
AYTU$59M
MRK$67.4B
MRK is 1,151 times AYTU
Net income, 12 months
AYTU-$20M
MRK$2.5B
Operating margin
AYTU-18.4%
MRK–
ROIC
AYTU-21.6%
MRK3.9%
25.5 points apart
P/E
AYTU–
MRK138.9
Dividend yield
AYTU0.0%
MRK2.5%
2.5 points apart
5-year return
AYTU-94.0%
MRK+98.6%
192.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AYTU-100.0%
MRK+98.6%
| Period | AYTUWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +27.3%Price +27.3% | +58.8%Price +54.3% |
| 3 years since November 17, 2023 | +16.2%+5.1% a yearPrice +16.2% | +54.4%+15.6% a yearPrice +40.9% |
| 5 years since November 16, 2021 | -94.0%-43.0% a yearPrice -94.0% | +98.6%+14.7% a yearPrice +70.5% |
| 10 years since November 18, 2016 | -100.0%-65.2% a yearPrice -100.0% | +229.5%+12.7% a yearPrice +142.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AYTUAytu BioPharmaMRKMerck & Company
| Price | $2.66 | $137.78 |
|---|---|---|
| Market value | $51M | $341B |
| Enterprise value (EV) | – | $385B |
| P/E | – | 138.9 |
| P/E, 5-year median | – | 14.8 |
| P/B | 1.6 | 7.6 |
| EV/EBIT | – | 80.8 |
| Free cash flow yield | 7.0% | 4.3% |
| Revenue, 12 months | $59M | $67.4B |
|---|---|---|
| Net income, 12 months | -$20M | $2.5B |
| Free cash flow, 12 months | $3.6M | $14.7B |
| Earnings per share, 12 months | -$1.52 | $0.98 |
| Revenue growth, year on year | -13.3% | 1.3% |
| Revenue growth a year, past | -2.6%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | 63.3% | 71.8% |
|---|---|---|
| Operating margin | -18.4% | – |
| Net margin | -34.3% | 3.6% |
| ROIC | -21.6% | 3.9% |
| ROE | -72.1% | 5.2% |
| Cash | $25M | $9.7B |
|---|---|---|
| Total debt | – | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | -6.0× | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.5% |
| Shareholder yield | – | 4.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($341B) is about 6,626.7 times Aytu BioPharma ($51M), at today's prices.
Since November 18, 2016, AYTU's price moved -100.0% and MRK's +142.8%. With dividends: AYTU -100.0% (-65.2% a year), MRK +229.5% (+12.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Aytu BioPharma and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
Over the last twelve months, the net margin was -34.3% for Aytu BioPharma and 3.6% for Merck & Company, and the operating margin -18.4% and –. Revenue was $59M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.